Thryv Therapeutics, Inc.
🇨🇦Canada
- Country
- 🇨🇦Canada
- Ownership
- Holding
- Established
- 2019-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.lqttrx.com
Study to Assess the Safety, Tolerability, Pharmacokinetic of Thrv-1268
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Thryv Therapeutics, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT06507839
- Locations
- 🇨🇦
Altasciences, Montreal, Quebec, Canada
Study of LQT-1213 on QTc-induced Prolongation in Healthy Adult Subjects (Part1) and on Congenital Long QT in Patients Diagnosed With Type 1, 2 or 3 Long QT Syndrome (Part 2).
Phase 1
Active, not recruiting
- Conditions
- Long QT Syndrome
- Interventions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- Thryv Therapeutics, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT05906732
- Locations
- 🇺🇸
Spaulding Clinical Research, LLC, West Bend, Wisconsin, United States
Phase 1 Study of LQT-1213 in Healthy Adults
- First Posted Date
- 2023-03-08
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- Thryv Therapeutics, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT05759962
- Locations
- 🇺🇸
Altasciences Clinical Los Angeles, Inc., Cypress, California, United States
© Copyright 2025. All Rights Reserved by MedPath